May 15, 2019 / 9:24 PM / 2 months ago

BRIEF-Roche says Entrectinib Shrank Tumors Harboring NTRK, ROS1 or ALK Gene Fusions In Children And Adolescents

May 15 (Reuters) - Roche Holding AG:

* GENENTECH’S PERSONALIZED MEDICINE ENTRECTINIB SHRANK TUMORS HARBORING NTRK, ROS1 OR ALK GENE FUSIONS IN CHILDREN AND ADOLESCENTS

* GENENTECH - SAFETY PROFILE OF ENTRECTINIB WAS CONSISTENT WITH THAT SEEN IN PREVIOUS ANALYSES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below